Logo

SPRC

SciSparc Ltd.

SPRC

SciSparc Ltd. • NASDAQ
$2.19 ▼ -1.35% (-0.03)
Market Cap $1.14 M
52w High $37.59
52w Low $1.75
Dividend Yield 0%
P/E 0.01
Volume 397.20K
Outstanding Shares 520.55K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $466K ▼ $10.875M ▲ $-2.842M ▲ -609.871% ▼ $1.7 ▲ $-3.666M ▼
Q2-2024 $840K ▼ $-3.053M ▲ $-3.442M ▼ -409.762% ▼ $-1.7 ▲ $-3.308M ▼
Q4-2023 $907K ▼ $-3.525M ▼ $-2.242M ▲ -247.189% ▼ $-4.07 ▲ $-2.582M ▲
Q2-2023 $1.972M ▲ $3.771M ▼ $-2.88M ▼ -146.045% ▼ $-10.85 ▼ $-2.7M ▲
Q4-2022 $1.347M $5.341M $3.167M 235.115% $13.83 $-3.347M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $2.057M ▼ $10.347M ▼ $1.408M ▼ $8.154M ▲
Q2-2024 $2.56M ▼ $10.482M ▼ $1.826M ▲ $6.92M ▼
Q4-2023 $5.076M ▲ $11.182M ▲ $1.595M ▼ $7.614M ▲
Q2-2023 $2.081M ▼ $9.892M ▼ $3.114M ▼ $4.096M ▼
Q4-2022 $3.574M $10.605M $4.156M $6.449M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-4.03M ▼ $-2.907M ▼ $-1.717M ▼ $5.912M ▲ $1.288M ▲ $-2.906M ▼
Q2-2024 $-3.442M ▼ $-2.197M ▲ $92K ▲ $281K ▼ $252K ▲ $-2.198M ▲
Q4-2023 $-2.242M ▲ $-2.654M ▲ $-38K ▲ $2.687M ▼ $60K ▲ $-2.654M ▲
Q2-2023 $-2.88M ▼ $-3.233M ▲ $-1.071M ▲ $2.811M ▲ $-1.553M ▲ $-3.233M ▲
Q4-2022 $3.167M $-5.729M $-6.376M $2.734M $-9.311M $-5.737M

Five-Year Company Overview

Income Statement

Income Statement SciSparc has effectively reported no revenue for several years, which is typical for an early‑stage biotech still in clinical development. Expenses are relatively small but steady, leading to recurring operating and net losses. The very large swings in earnings per share mostly reflect share count changes and reverse splits rather than a sudden shift in the underlying business. Overall, this is still a pre‑commercial, loss‑making company whose financial story is about research progress rather than sales or profits.

Balance Sheet

Balance Sheet The balance sheet is very small and simple: modest assets, minimal cash, no reported debt, and equity that roughly matches total assets. This suggests a lean, asset‑light structure but also limited financial resources to fund long development timelines. The absence of debt removes interest‑burden risk, but the small capital base likely means continued reliance on raising new funding if the pipeline is to move forward meaningfully.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting ongoing research, clinical, and corporate costs without offsetting revenue. Capital spending appears minimal, so cash burn is mainly tied to operating activities rather than heavy investment in facilities or equipment. While the absolute burn looks modest, the company’s small cash position means that even limited outflows can be important, and future funding needs are a key watchpoint.

Competitive Edge

Competitive Edge SciSparc operates in highly competitive areas: central nervous system disorders using cannabinoid‑based therapies and, via its device acquisition, treatment of reflux disease. Its edge comes from proprietary cannabinoid combinations, use of an accelerated regulatory pathway, and a focus on underserved niche indications like Tourette Syndrome and certain Alzheimer’s‑related symptoms. However, it competes against far larger pharmaceutical and device players, and without approved products yet, its competitive position is still more potential than proven.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece: proprietary THC/CBD–PEA formulations, a portfolio of patents, and the use of quantum computing for drug discovery all point to a research‑driven strategy. The pipeline includes multiple clinical programs and a move into a commercial‑stage medical device for reflux, plus collaborations on next‑generation neuropsychiatric treatments. The upside is meaningful optionality across drugs and devices, but there is classic biotech risk: clinical failures, regulatory hurdles, and execution challenges could all limit how much of this innovation ultimately turns into sustainable revenue.

Summary

SciSparc is an early‑stage, pre‑revenue biotech with a very small balance sheet, recurring but relatively modest losses, and ongoing negative cash flow that will likely require additional funding over time. Its value story rests on a diversified set of innovations—cannabinoid‑based therapies, a GERD medical device, and advanced discovery techniques—rather than on current financial performance. The company sits at a pivotal, high‑uncertainty phase: progress in clinical trials and successful commercialization of its device could materially change its profile, while setbacks or funding constraints would be significant risks to its longer‑term prospects.

NEWS

November 26, 2025 · 7:38 AM UTC

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

Read more

November 20, 2025 · 6:42 AM UTC

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Read more

October 24, 2025 · 7:55 AM UTC

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Read more

October 23, 2025 · 4:03 PM UTC

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Read more

October 23, 2025 · 8:55 AM UTC

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Read more